Edition:
United States

Adamis Pharmaceuticals Corp (ADMP.PH)

ADMP.PH on Philadelphia Stock Exchange

5.25USD
3:51pm EDT
Change (% chg)

$0.30 (+6.06%)
Prev Close
$4.95
Open
$5.10
Day's High
$5.30
Day's Low
$5.10
Volume
4,757
Avg. Vol
3,304
52-wk High
$6.45
52-wk Low
$2.47

ADMP.PH

Chart for ADMP.PH

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.10
Market Cap(Mil.): $136.44
Shares Outstanding(Mil.): 27.56
Dividend: --
Yield (%): --

Financials

  ADMP.PH Industry Sector
P/E (TTM): -- 13.97 18.98
EPS (TTM): -1.07 -- --
ROI: -112.75 -6.80 -5.09
ROE: -136.44 -6.26 -4.32

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Jun 15 2017

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Jun 15 2017

UPDATE 2-Adamis wins U.S. approval to sell EpiPen rival, shares soar

June 15 Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Jun 15 2017

Adamis gets U.S. approval to sell EpiPen rival, shares soar

June 15 Adamis Pharmaceuticals on Thursday said it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that would compete with Mylan's widely used EpiPen, sending its shares up 50 percent.

Jun 15 2017

BRIEF-Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe

* Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe

Jun 15 2017

BRIEF-Adamis Pharmaceuticals announces closing of public offering

* Adamis Pharmaceuticals announces closing of public offering of common stock and exercise of over-allotment option in full Source text for Eikon: Further company coverage:

Apr 26 2017

BRIEF-Perceptive Advisors reports 5.57 pct stake in Adamis Pharma

* Perceptive Advisors LLC reports 5.57 percent passive stake in Adamis Pharmaceuticals Corp as of April 21 - SEC filing Source text: (http://bit.ly/2p9rcOW) Further company coverage:

Apr 24 2017

BRIEF-Adamis Pharmaceuticals announces pricing of public offering of common stock

* Adamis Pharmaceuticals announces pricing of public offering of common stock

Apr 21 2017

BRIEF-Adamis Pharmaceuticals announces proposed public offering of common stock

* Adamis Pharmaceuticals announces proposed public offering of common stock

Apr 20 2017

BRIEF-Adamis Pharmaceuticals announces FDA acceptance of its Epinephrine Pre-filled Syringe

* Adamis Pharmaceuticals announces FDA acceptance of resubmission of its Epinephrine pre-filled syringe NDA Source text for Eikon: Further company coverage:

Jan 19 2017

More From Around the Web

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,722.00 +39.00

Earnings vs. Estimates